Reader View AI Reader View Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy? www.nasdaq.com · November 9, 2026 · 20:38 Paywall detected This article has a paywall The publisher blocks direct access to this article. Generate with AI Open link